168 related articles for article (PubMed ID: 22235956)
1. Analysis of nonformulary use of PPIs and excess drug cost in a Veterans Affairs population.
Ajumobi AB; Vuong R; Ahaneku H
J Manag Care Pharm; 2012; 18(1):63-7. PubMed ID: 22235956
[TBL] [Abstract][Full Text] [Related]
2. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
Linton A; Bacon T; Peterson M
J Manag Care Pharm; 2009; 15(1):42-54. PubMed ID: 19125549
[TBL] [Abstract][Full Text] [Related]
3. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
Johnson JT; Neill KK; Davis DA
J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
[TBL] [Abstract][Full Text] [Related]
4. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
[TBL] [Abstract][Full Text] [Related]
5. Variation in Formulary Management Practices Within the Department of Veterans Affairs Health Care System.
Radomski TR; Good CB; Thorpe CT; Zhao X; Marcum ZA; Glassman PA; Lowe J; Mor MK; Fine MJ; Gellad WF
J Manag Care Spec Pharm; 2016 Feb; 22(2):114-20. PubMed ID: 27015250
[TBL] [Abstract][Full Text] [Related]
6. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
[TBL] [Abstract][Full Text] [Related]
7. Physician satisfaction with formulary policies: is it access to formulary or nonformulary drugs that matters most?
Glassman PA; Good CB; Kelley ME; Bradley M; Valentino M
Am J Manag Care; 2004 Mar; 10(3):209-16. PubMed ID: 15032258
[TBL] [Abstract][Full Text] [Related]
8. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
Lucas LM; Gerrity MS; Anderson T
Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
[TBL] [Abstract][Full Text] [Related]
9. Multicenter drug use evaluation of tamsulosin and availability of guidance criteria for nonformulary use in the veterans affairs health system.
Burk M; Furmaga E; Dong D; Cunningham F
J Manag Care Pharm; 2004; 10(5):423-32. PubMed ID: 15369425
[TBL] [Abstract][Full Text] [Related]
10. Formulary management of proton pump inhibitors.
Byrne MF; Murray FE
Pharmacoeconomics; 1999 Sep; 16(3):225-46. PubMed ID: 10558037
[TBL] [Abstract][Full Text] [Related]
11. Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar.
Al-Badriyeh D; Alabbadi I; Fahey M; Al-Khal A; Zaidan M
Clin Ther; 2016 May; 38(5):1158-73. PubMed ID: 27021610
[TBL] [Abstract][Full Text] [Related]
12. Effect of a therapeutic maximum allowable cost (MAC) program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada.
Mabasa VH; Ma J
J Manag Care Pharm; 2006 Jun; 12(5):371-6. PubMed ID: 16792443
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study.
Liu Y; Zhu X; Li R; Zhang J; Zhang F
BMJ Open; 2020 Nov; 10(11):e040473. PubMed ID: 33243802
[TBL] [Abstract][Full Text] [Related]
14. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities.
Patterson Burdsall D; Flores HC; Krueger J; Garretson S; Gorbien MJ; Iacch A; Dobbs V; Homa T
J Am Med Dir Assoc; 2013 Jun; 14(6):429-32. PubMed ID: 23583000
[TBL] [Abstract][Full Text] [Related]
15. Pharmacy costs associated with nonformulary drug requests.
Sweet BV; Stevenson JG
Am J Health Syst Pharm; 2001 Sep; 58(18):1746-52. PubMed ID: 11571818
[TBL] [Abstract][Full Text] [Related]
16. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
17. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
Haastrup PF; Paulsen MS; Christensen RD; Søndergaard J; Hansen JM; Jarbøl DE
Aliment Pharmacol Ther; 2016 Jul; 44(1):78-87. PubMed ID: 27137875
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones.
Walbrown MA; Aspinall SL; Bayliss NK; Stone RA; Cunningham F; Squier CL; Good CB
J Manag Care Pharm; 2008; 14(1):34-40. PubMed ID: 18240880
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic management of uncomplicated gastroesophageal reflux disease in france in 2005: Potential cost savings of omeprazole substitution.
Mouly S; Charlemagne A; Lejeunne P; Fagnani F
Curr Ther Res Clin Exp; 2009 Aug; 70(4):282-98. PubMed ID: 24683238
[TBL] [Abstract][Full Text] [Related]
20. The influence of hospital drug formulary policies on the prescribing patterns of proton pump inhibitors in primary care.
Larsen MD; Schou M; Kristiansen AS; Hallas J
Eur J Clin Pharmacol; 2014 Jul; 70(7):859-65. PubMed ID: 24770928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
